PharmaShots | Incisive News in 3 Shots

Subscribe Now

FDA

FDA Launches a Pilot Program to Regulate the Safety Standards Associated with In vitro Diagnostic Tests to Identify Cancer Biomarkers

FDA Launches a Pilot Program to Regulate the Safety Standards Associated with In vitro Diagnostic Tests to Identify Cancer Biomark...

June 23, 2023

Alnylam’s Amvuttra (vutrisiran) Receives the US FDA’s Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Alnylam’s Amvuttra (vutrisiran) Receives the US FDA’s Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

June 14, 2022

Glenmark’s Ryaltris Nasal Spray Receives the US FDA’s Approval for the Treatment of Seasonal Allergic Rhinitis

Glenmark’s Ryaltris Nasal Spray Receives the US FDA’s Approval for the Treatment of Seasonal Allergic Rhinitis

January 14, 2022

OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF

OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF

November 18, 2021

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

November 12, 2021

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

November 3, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us